views

SkinBioTherapeutics – interims, Mr Market has it wrong. Strong Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2022 and the shares have been marked down in response. Mr Market has got it wrong and this is a Strong Buy.

views

Defamatory Bulletin Board Moron of the week: beinthelead on the LSE Asylum, re Skinbiotherapeutics

It is hard to know where to start with this utter cretin. But for starters I do not post on BBs in my own name or as Truatnt2tb as this fool alleges in a defamatory manner.

NEWSFLOW

SkinBioTherapeutics (#SBTX) – Spain health authority authorisation for psoriasis product AxisBiotix-Ps to enable start of geographic expansion

views

Lemming interviews Skinbiotherapeutics boss Stuart Ashman

I do not always agree with Mr Lemming Investor but for what it is worth we are both still bulls of Skinbiotherapeutics (SBTX). He posted this Q&A with Stuart Ashman the other day and it is worth a read. Over to the Lemming:

views

SkinBioTherapeutics – no-one watching o’clock results and equity raise, what’s the outlook from here?

SkinBioTherapeutics (SBTX) has announced no-one watching o’clock (4:30pm) results for its year ended 30^th June 2022, with CEO Stuart Ashman stating “this financial year has been a mixed one for the group”. With the results coming with a potentially £3.5 million equity raise (albeit including an up to £1 million “retail offer”) at 16p per share, we’ve got some other words for it but where does this all leave the company now?

NEWSFLOW

SkinBioTherapeutics (#SBTX) – placing raises £2.5m at 16p per share, notes also “retail offer”

views

I am branded Mr Angry - Lemming Investor video interview with Stuart Ashman of Skinbiotherapeutics

Let us be clear. When I said that Staurt Ashman said that month on month sales doubled in both July and August I said so because the bearded loon said so in an email to me. For him to backtrack as he does in this interview and suggest that "Mr Angry" is a bit confused, therefore makes me a bit more er....angry. If you have an hour of your life to spare, enjoy.

NEWSFLOW

SkinBioTherapeutics (#SBTX) – updates on AxisBiotix-PS sales progress with original sales lower than forecast, notes out-licensing discussions and Oral programme progress

views

SkinBioTherapeutics – interim numbers & warning of slight delay largely irrelevant, the clear potential remains - Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

NEWSFLOW

SkinBioTherapeutics (#SBTX) – H1 cash down by £1.5m to £3.2m, AxisBiotix-Ps current sales “materially below budget” but marketing campaign now initiated